abstract |
The invention is directed to a process and intermediates for the preparation of 1 alpha ,25-dihydroxyergocalciferol as well as substantially pure and crystalline 1 alpha ,25-dihydroxyergocolciferol. The end-product 1 alpha ,25-dihydroxyergocalciferol is useful in the treatment of disease states which are characterized by insufficient amounts of 1 alpha ,25-dihydroxycholecalciferol. |